About Propagenix
Propagenix is a company based in Gaithersburg (United States) founded in 2014 was acquired by Stem Cell Technologies in January 2024. Propagenix has raised $8.8 million across 6 funding rounds from investors including Stem Cell Technologies, HHS and Maryland Stem Cell Research Fund. Propagenix operates in a competitive market with competitors including Enlivex Pharmaceuticals, Orgenesis, Sernova, TissueGene and LyGenesis, among others.
- Headquarter Gaithersburg, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.8 M (USD)
in 6 rounds
-
Latest Funding Round
$182.85 K (USD), Grant
Jan 15, 2021
-
Investors
Stem Cell Technologies
& 2 more
-
Employee Count
Not available
-
Acquired by
Stem Cell Technologies
(Jan 19, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Propagenix
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Propagenix
Propagenix has successfully raised a total of $8.8M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $182.85 thousand completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Propagenix
Propagenix has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Stem Cell Technologies, HHS and Maryland Stem Cell Research Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stem cell research startups in healthcare are funded and accelerated.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Developer of cell culture media and ancillary reagents for life science research
|
Locked | Locked | Locked |
Investor details for Propagenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Propagenix
Investment portfolio details for Propagenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Propagenix
Detailed financials for Propagenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Propagenix Comparisons
Peer comparison for Propagenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Propagenix
Propagenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enlivex Pharmaceuticals, Orgenesis, Sernova, TissueGene and LyGenesis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Autologous and allogeneic cell immunotherapies are developed for autoimmune conditions.
|
|
| Locked | Locked | Locked |
Cell and gene therapies for multiple disorders are developed.
|
|
| Locked | Locked | Locked |
Regenerative medicine to deliver proteins and hormones for disease treatment
|
|
| Locked | Locked | Locked |
Regenerative cell therapies for orthopedic diseases are developed.
|
|
| Locked | Locked | Locked |
Regenerative medicines for liver disorders are developed using lymph nodes.
|
Detailed competitors of Propagenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Propagenix
Complete news archive for Propagenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Propagenix
Propagenix was founded in 2014.
Propagenix is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Propagenix is a funded company, having raised a total of $8.8M across 6 funding rounds to date.
Propagenix is an RD-stage cell therapy company engaged in the development of the primary cells, tumor cell models and cell therapies. It is currently focussed on continuing the development of Conditional Replication (CR) technology that generates unlimited quantities of biologically important cell types ex vivo that retain the ability to re-adopt the relevant functionality of the tissues from which the cells originated. It has developed multiple human and other mammalian cell cultures and stable cell lines from tumor cells. Besides, it has a set of cell therapy preclinical-stage programs related to pancreatic diseases, autologous skin engraftment and airway injury and respiratory diseases.
Propagenix's top competitors include Enlivex Pharmaceuticals, Sernova and Emmaus Medical.
Propagenix has 3 investors. Key investors include Stem Cell Technologies, HHS, and Maryland Stem Cell Research Fund.